Liztox vs Xeomin
Liztox
Published by
Last Updated On July 1, 2024

Liztox vs Xeomin – Comparing Botulinum Toxins

Jun 7, 2024

Botulinum toxins are one of the world’s most popular minimally invasive cosmetic procedures. In the United States, healthcare professionals administered over 9 million botulinum toxin injections in 2022, signifying this treatment’s popularity for facial rejuvenation.

Among the various products available, Liztox and Xeomin are two alternatives to Botox. While they effectively smooth wrinkles by temporarily blocking nerve signals to targeted muscles, each is renowned for its unique efficacy and favorable safety profiles. They offer patients compelling and individualized options for achieving their desired cosmetic enhancements.

This article compares Liztox and Xeomin, exploring their mechanisms, effectiveness, safety, and potential outcomes to help readers make informed decisions about their aesthetic journey.

Key Takeaways

  • Liztox and Xeomin help smooth lines and improve muscle tone. They work by relaxing muscles but have different compositions.
  • Liztox might come with extra proteins, while Xeomin is a pure form of botulinum toxin type A, which may make it act faster in some cases.
  • Choosing between them depends on how quickly results are wanted, previous reactions to treatments, and personal or doctor recommendations.
  • Side effects for both can include things like headache or pain at the injection site, but severe side effects are rare.
  • The correct dose and administration technique are essential for safety and good results with Liztox and Xeomin.

About: Trusted by over 2,000+ global clients since 2014, Maylips has become a leading supplier of cosmetic, skincare, and orthopedic products for medical and aesthetic professionals. Maylips offers a wide range of authentic brand-name products at competitive wholesale prices, sourced from around the world. If you’re looking to buy Liztox, contact our sales team for guidance.

Introduction to Liztox and Xeomin

Liztox and Xeomin offer practical solutions for wrinkle smoothing and muscle tone improvement. Research suggests Xeonom might have a faster onset in anti-aging treatments than Botox. 

Understanding their differences in formulation, action mechanisms, and trial outcomes aids informed decision-making for medical professionals. Considering safety, dose advice, and patient preferences will help determine the preferred option for individual cases.

Botulinum toxin products like Liztox and Xeomin are versatile in cosmetic and therapeutic applications. While Xeomin offers a purified form of botulinum toxin type A, Liztox’s reviews highlight its effectiveness across various uses. 

Medical professionals must closely compare these options, considering factors like the onset of action and safety profiles. Understanding their formulation differences, such as Liztox’s protein mixture compared to Xeomin’s pure botulinum Type A composition, is crucial. 

Formulation and Composition

Liztox distinguishes itself in the botulinum toxin market. Due to its innovative formulation, it’s a preferred choice for practitioners compared to Botox or Xeomin. Liztox’s blend of proteins around the botulinum toxin caters to diverse aesthetic and therapeutic needs, evolving beyond traditional applications to ensure safety and efficiency.

Meanwhile, Xeomin’s pure botulinum toxin Type A composition sets it apart, devoid of extra proteins in other brands. This feature facilitates faster action and is ideal for swift wrinkle reduction and muscle relaxation. Its formulation potentially elicits fewer immune responses over repeated treatments, ensuring lasting effects with minimal injections. 

Dilution charts ensure safe Liztox use, while Xeomin’s lack of complexing proteins may reduce antibody formation concerns. Both formulations offer unique benefits, requiring careful consideration of individual patient needs and preferences.

Mechanism of Action

Liztox targets the muscles where it’s injected. It blocks nerve signals that make muscles contract, causing the muscles to relax and smooth out lines or wrinkles. This effect helps reduce signs of aging or treat medical conditions like muscle spasticity. It starts soon after injection and shows results in a few days. Liztox’s action on nerves is temporary, so treatments must be repeated for maintenance.

Similarly, Xeomin blocks signals from the nerves to the muscles, which stops the muscle from contracting, helping smooth lines and wrinkles. Since Xeomin is a purified form of botulinum toxin type A without additional proteins, it works directly where injected, making its action both targeted and effective for treating specific areas.

Efficacy in Aesthetic and Therapeutic Treatments

An ongoing study is being conducted to test how well Liztox works and how safe it is for treating benign masseteric hypertrophy. This study is carefully planned and will involve many different medical centers. The goal is to see if Liztox can reduce the size of the masseter muscle using a special kind of imaging called ultrasonography.

While awaiting the trial’s outcomes, such rigorous investigations are instrumental in understanding Liztox’s side effects and safety profile as a medical intervention. Individuals considering Liztox treatment should engage in thorough discussions with their healthcare provider to fully comprehend the associated risks and benefits.

As for Xeomin, two pivotal phase 3 clinical studies on Xeomin by Merz Aesthetics showed promising results for treating upper facial lines, including forehead and frown lines. Xeomin demonstrated a significantly higher response rate, with well-tolerated treatment-related adverse events.

These findings support an upcoming regulatory filing with the FDA, affirming Xeomin’s established efficacy and safety profile with nearly 15 years of global clinical experience.

Safety Profiles

Understanding the safety profiles of Liztox and Xeomin is crucial for medical professionals to make informed treatment decisions. The table below highlights the key aspects of their safety profiles based on adverse reactions, FDA approval status, and clinical observations. This comparison aims to equip practitioners with concise, relevant information, facilitating a choice that best suits the patient’s needs.

AspectLiztoxXeomin
Adverse ReactionsPossible muscle weakness, headache, injection-site painSimilar to Liztox, with occasional dry mouth or fatigue
Clinical ObservationsNo significant differences in safety profile compared to other botulinum toxinsSafety and efficacy profiles similar to Botox, with some reports of faster onset in anti-aging treatments

Practical Considerations

When administering Liztox and Xeomin, precise dosing is vital. Dose adjustments consider treatment area variations; for instance, forehead lines may require different amounts than crow’s feet. A thorough medical history evaluation ensures patient safety. Tracking initial Liztox responses aids in tailoring subsequent treatments, emphasizing starting with the lowest effective dose to mitigate risks. 

Xeomin dosages vary by treatment area, typically starting at 20 units for frown lines and up to 25 units per eye for eyelid spasms. Cervical dystonia doses may range from 120 to 240 units, adjusted based on severity and response. Patient age, muscle mass, and previous botulinum toxin reactions influence dosage adjustments.

Administration Techniques for Liztox and Xeomin

After discussing the dosage recommendations for Liztox and Xeomin, it’s crucial to understand how these are administered. Both require precise techniques to ensure safety and effectiveness.

  • Cleanse the skin with an antiseptic solution to prevent infections before injection.
  • Use a non-permanent marker to mark injection spots accurately.
  • Draw the prescribed toxin amount into a sterile syringe, ensuring no air bubbles.
  • Select a fine, short needle for facial injections to minimize discomfort and bruising.
  • Inject superficially under the skin or into muscles as needed for facial treatments.
  • Apply gentle pressure post-injection to prevent bruising, avoiding massaging the area.
  • Monitor the patient closely post-injection for adverse reactions.
  • Provide clear aftercare instructions, including avoiding facial touching and remaining upright.
  • Schedule a follow-up appointment to assess the effects and determine further treatment.
  • Document dosage, treated areas, patient reactions, and follow-up plans for future reference and improvement.

Conclusion

Liztox and Xeomin both smooth lines and improve muscle tone. They have similarities but also unique features. Matching patient needs with the right product is crucial. Choosing between the two comes down to personal preference and clinical goals.

FAQs

1. What’s the main difference between Liztox and Xeomin?

Liztox has added proteins around the toxin, while Xeomin is a pure toxin without these extras.

2. Can both Liztox and Xeomin be used for wrinkles?

Yes, both are used to smooth out wrinkles on the face.

3. How long does it take to see results from Liztox or Xeomin?

You’ll start seeing results about 1-2 weeks after getting either treatment.

4. Do Liztox and Xeomin last the same amount of time?

Nope, how long they last can vary from person to person but generally ranges from 3 to 6 months.

5. Is one safer than the other?

Both are considered safe when done by a professional, but your doctor can help you decide which is better for you.

Need help, additional info, or customized deals?

Talk with our sales representative.

Book a Meeting

References

American Society of Plastic Surgeons. American Society of Plastic Surgeons. American Society of Plastic Surgeons. Published 2022. https://www.plasticsurgery.org/news/plastic-surgery-statistics

Kwak S, Kang W, Rhee CH, Yang GH, Cruz DJM. Comparative Pharmacodynamics Study of 3 Different Botulinum Toxin Type A Preparations in Mice. Dermatologic Surgery. 2020;46(12):e132-e138. doi:https://doi.org/10.1097/dss.0000000000002402 

Huons Biopharma. A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of LIZTOX in Subjects With Benign Masseteric Hypertrophy. clinicaltrials.gov. Published July 26, 2023. Accessed June 8, 2024. https://classic.clinicaltrials.gov/ct2/show/NCT05964257